News dated
Gavi and UNICEF announced an agreement on 22 October to bring the price of the RTS,S/AS01 malaria vaccine to €5.50 per dose, a reduction of about 40%. The price is expected from early 2027, subject to manufacturing and regulatory milestones, including WHO prequalification of a new facility before procurement. [1][2]
The organisations project savings of around US$50 million over 2027–2029. That is a forecast, not money already saved or doses already delivered. The completed step is the agreement; its contribution to access depends on meeting the conditions and on subsequent supplies. [1][2]
The bright side
The agreement could expand vaccine programmes’ purchasing possibilities if the manufacturing and regulatory conditions are met. [1][2]
One idea, in simple words
Gavi and UNICEF help organise access to vaccines. On 22 October they announced an agreement on the price of a malaria vaccine. The planned price is €5.50 per dose, about 40% lower. A dose is an amount of vaccine intended for one administration. The change is expected from early 2027, but checks and manufacturing steps must be completed first. It is therefore not a price already in use today. Imagine a group with a fixed budget for materials: if each item costs less, it could buy more. This is an example explaining a possibility, not a promise of deliveries. The announced savings are still an estimate for the future. [1][2]
A little discovery to keep
What did you discover?
Straight from the source.
- Gavi and UNICEF secure lower malaria vaccine price, saving US$50 million for childhood immunization programmes UNICEF · 22 Oct 2026
- Gavi and UNICEF secure lower malaria vaccine price, saving US$50 million for childhood immunization programmes Gavi · 22 Oct 2026
Original reporting summaries prepared with AI assistance and accessible sources. Our editorial method.
